Ruffer LLP Purchases 623,552 Shares of Pfizer Inc. $PFE

Ruffer LLP increased its position in Pfizer Inc. (NYSE:PFE) by 44.6% during the 3rd quarter, Holdings Channel.com reports. The firm owned 2,023,065 shares of the biopharmaceutical company’s stock after purchasing an additional 623,552 shares during the period. Pfizer comprises 2.9% of Ruffer LLP’s investment portfolio, making the stock its 11th largest position. Ruffer LLP’s holdings in Pfizer were worth $51,547,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the business. Curio Wealth LLC lifted its position in Pfizer by 36,600.0% during the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 1,098 shares during the period. Harbor Asset Planning Inc. bought a new position in shares of Pfizer during the second quarter valued at approximately $29,000. Grey Fox Wealth Advisors LLC purchased a new position in shares of Pfizer during the third quarter valued at approximately $29,000. Howard Hughes Medical Institute bought a new position in Pfizer during the 2nd quarter valued at approximately $30,000. Finally, Darwin Wealth Management LLC purchased a new position in Pfizer during the second quarter valued at $32,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

NYSE PFE opened at $25.89 on Thursday. The stock has a market capitalization of $147.17 billion, a price-to-earnings ratio of 15.05 and a beta of 0.47. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $27.69. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. The business’s fifty day moving average price is $25.45 and its 200-day moving average price is $25.01.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. The company had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.6%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s dividend payout ratio is currently 100.00%.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Sanford C. Bernstein restated a “market perform” rating and set a $30.00 price target on shares of Pfizer in a report on Friday, October 31st. Bank of America cut their price target on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a report on Monday, December 15th. Zacks Research downgraded Pfizer from a “hold” rating to a “strong sell” rating in a research note on Monday. Morgan Stanley decreased their price target on Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a research note on Friday, December 12th. Finally, TD Cowen reaffirmed a “hold” rating on shares of Pfizer in a research report on Tuesday, December 30th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $28.06.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.